Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2021

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-688F]

Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2021

AGENCY:

Drug Enforcement Administration, Department of Justice.

ACTION:

Final order.

SUMMARY:

This final order establishes the final adjusted 2021 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

DATES:

This order is effective November 15, 2021.

FOR FURTHER INFORMATION CONTACT:

Scott A. Brinks, Regulatory Drafting and Policy Support Section, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, VA 22152, Telephone: (571) 362-3261.

SUPPLEMENTARY INFORMATION:

Legal Authority

Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas (APQ) for each basic class of controlled substances listed in schedules I and II and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The Attorney General has delegated this function to the Administrator of the Drug Enforcement Administration (DEA) pursuant to 28 CFR 0.100.

Background

DEA published the 2021 established APQ for controlled substances in schedules I and II and for the assessment of annual needs (AAN) for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine in the

Federal Register

on November 30, 2020. 85 FR 76604. DEA is committed to preventing and limiting diversion by enforcing laws and regulations regarding controlled substances and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, while meeting the legitimate medical, scientific, and export needs of the United States. This notice stated that the Administrator would adjust, as needed, the established APQ in 2021 in accordance with 21 CFR 1303.13 and 21 CFR 1315.13.

The 2021 proposed adjusted APQ for controlled substances in schedules I and II and AAN for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine were subsequently published in the

Federal Register

on September 2, 2021, (86 FR 49346), after consideration of the criteria outlined in that notice. All interested persons were invited to comment on or object to the proposed APQs and AANs on or before October 4, 2021.

Comments Received

DEA received 27 timely comments in response to the September

Federal Register

notice from patients, DEA-registered entities, and non-DEA entities. The comments included appreciation of DEA's response to the increased interest in research using hallucinogenic controlled substances, requests to increase the APQ for additional hallucinogenic controlled substances, requests to increase the APQ for select schedule II controlled substances, concerns regarding the inability to comment to the notice electronically for two weeks, and comments outside the scope of this final order.

Issue:

Commenters expressed appreciation of DEA's flexibility in responding to the nationwide public interest in hallucinogenic controlled substances research.

DEA Response:

DEA acknowledges the expressions of appreciation to changes in the APQ for these controlled substances. The adjustments to select hallucinogenic schedule I controlled substances occurred after DEA received additional schedule I researcher protocols from DEA registered researchers and quota applications from DEA registered manufacturers.

Issue:

Commenters requested DEA to increase the APQ for Bufotenine, Dimethyltryptamine (DMT), N,N-Dimethyltryptamine, 5-Methoxy-N,N-

dimethyltryptamine (5MEODMT), Ibogaine, Ketamine, Lysergic Acid Diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (MDMA), Mescaline, Mitragynine, and Psilocybin in response to the nationwide public interest in hallucinogenic controlled substances research.

DEA Response:

Ketamine is a schedule III controlled substance and therefore is outside of the scope of this final order as DEA only sets APQs for substances controlled in schedules I and II. DEA received additional quota applications for DMT, MDMA, and Psilocybin and considered the timely provided information in those applications for this final order. Regarding the other controlled substances listed, DEA has not received quota applications from DEA-registered manufacturers to support the requested changes in the APQ for these controlled substances. Mitragynine is not a controlled substance and therefore is outside the scope of this final order.

Issue:

DEA-registered entities requested that the APQ for Methadone, Methadone Intermediate, Methylphenidate Oxycodone (for sale), Phenylacetone, and Thebaine be sufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, for export requirements, and for the establishment and maintenance of reserve stocks.

DEA Response:

DEA sets APQ in a manner to ensure that the estimated medical, scientific, research, industrial needs of the United States, lawful export requirements, and for the establishment and maintenance of reserve stocks. As discussed in the notice for adjustment, any adjustments to the APQ for a controlled substance are based on factors set forth in 21 CFR 1303.13. In the event of a shortage, the CSA provides a mechanism under which DEA will, in appropriate circumstances, increase quotas to address shortages. 21 U.S.C. 826(h). Under 21 U.S.C. 826(h)(1), after receiving a request to address a shortage, DEA has 30 days to complete review of the request and determine whether adjustments are necessary to address the shortage. If adjustments are necessary, DEA is required to increase the APQ and individual production quotas to alleviate the shortage.

Id.

If DEA determines adjustments are not necessary, DEA is required to “provide a written response detailing the basis for the . . . determination.”

Id.

In addition to what Section 826(h)(1) requires, when DEA is notified of an alleged shortage, DEA will confer with the Food and Drug Administration and relevant manufacturers regarding the amount of material in physical inventory, current quota granted, and the estimated legitimate medical need, to determine whether a quota adjustment is necessary to alleviate any quota-related drug shortage.

In accordance with 21 CFR 1303.13, DEA considered the comments for Bufotenine, 5-Methoxy-N,N-dimethyltryptamine (5MEODMT), Ibogaine, Lysergic Acid Diethylamide (LSD), Mescaline, Methadone, Methadone Intermediate, Oxycodone (for sale), and Thebaine and the Administrator determined the proposed adjusted 2021 APQs for these substances as published in the

Federal Register

on September 2, 2021, (86 FR 49346), are sufficient to meet the current 2021 estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and to provide for adequate reserve stock.

Issue:

Commenters expressed general concerns regarding the inability to submit electronic comments to the notice published on September 2, 2021, for two weeks. Commenters requested an extension of the comment period to allow for additional comments.

DEA Response:

DEA acknowledges that commenters could not submit electronic comments to the notice for two weeks. However, written comments could be submitted via mail to the address provided in the notice. Written comments that were postmarked on or before October 4, 2021, were considered in this final order. DEA notes that one commenter submitted identical electronic and written comments both of which were timely postmarked, received, and considered for this final order.

Out of Scope Comments:

DEA received comments on issues outside the scope of this final order. Commenters made several suggestions to the DEA, including: (1) Seeking assistance from indigenous communities to determine the amount of psychedelic substances that would be needed to conduct research; (2) making the United States a signatory to the

Nagoya Protocol and the Convention on Biological Diversity;

and (3) creating diversified categories for production and research on psilocybin-containing fungi fruiting bodies/sclerotia/liquid culture similar to cannabis (flower), fruiting body extract (akin to cannabis extract), and psilocybin and psilocin separately as purified compounds (akin to delta-9-thc). Regarding this last suggestion, the commenter further suggested that the “same system should then be replicated in regards to lophophora/mescaline, as well as other plants, fungi and lifeforms, which produce these compounds being used in whole or closer to whole ways.”

DEA received other comments that were general in nature and raised issues of specific medical illnesses and medical treatments. All of the issues raised are outside of the scope of this final order for 2021 and do not impact the original analysis involved in finalizing the 2021 APQ.

Analysis for Final Adjusted 2021 Aggregate Production Quotas and Assessment of Annual Needs

In determining the final adjusted 2021 APQ and AAN, DEA considered the above comments relevant to this final order for calendar year 2021, along with the factors set forth in 21 CFR 1303.13 and 21 CFR 1315.13, in accordance with 21 U.S.C. 826(a). DEA has also considered other relevant factors, including the 2020 year-end inventories, initial 2021 manufacturing and import quotas, 2021 export requirements, actual and projected 2021 sales, research and product development requirements, additional applications received, and the extent of any diversion of the controlled substance in the class. Based on all of the above, the Administrator is adjusting the 2021 APQ for the following: 3,4-Methylenedioxymethamphetamine (MDMA), 4,4′-Dimethylaminorex, Dimethyltryptamine (DMT), Lisdexamfetamine, Methiopropamine, Psilocybin, Psilocyn, and Phenylacetone. This final order reflects those adjustments.

Pursuant to the above, the Administrator hereby finalizes the 2021 APQ for the following schedule I and II controlled substances and the 2021 AAN for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows:

Basic class

Final adjusted 2021

quotas

(g)

Schedule I

1-[1-(2-Thienyl)cyclohexyl]pyrrolidine

20

1-(1-Phenylcyclohexyl)pyrrolidine

30

1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine

10

1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)

30

1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)

30

1-Benzylpiperazine

25

1-Methyl-4-phenyl-4-propionoxypiperidine

10

1-[1-(2-Thienyl)cyclohexyl]piperidine

15

2'-fluoro 2-fluorofentanyl

30

2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)

30

2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)

30

2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)

30

2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P)

30

2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)

100

2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)

30

2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)

30

2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82)

25

2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)

30

2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5)

30

2,5-Dimethoxy-4-ethylamphetamine (DOET)

25

2,5-Dimethoxy-4-n-propylthiophenethylamine

25

2,5-Dimethoxyamphetamine (DMA)

25

2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)

30

2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)

30

3,4,5-Trimethoxyamphetamine

30

3,4-Methylenedioxyamphetamine (MDA)

55

3,4-Methylenedioxymethamphetamine (MDMA)

3,200

3,4-Methylenedioxy-N-ethylamphetamine (MDEA)

40

3,4-Methylenedioxy-N-methylcathinone (methylone)

40

3,4-Methylenedioxypyrovalerone (MDPV)

35

3-FMC; 3-Fluoro-N-methylcathinone

25

3-Methylfentanyl

30

3-Methylthiofentanyl

30

4′-Methyl acetyl fentanyl

30

4,4'-Dimethylaminorex

30

4-Bromo-2,5-dimethoxyamphetamine (DOB)

30

4-Bromo-2,5-dimethoxyphenethylamine (2-CB)

25

4-Chloro-α-pyrrolidinovalerophenone (4-chloro-alpha-PVP)

25

4CN-Cumyl-Butanica, 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboximide

25

4F-MDMB-BINACA

30

4-Fluoroisobutyryl fentanyl

30

4-FMC; Flephedrone

25

4-MEC; 4-Methyl-N-ethylcathinone

25

4-Methoxyamphetamine

150

4-Methyl-2,5-dimethoxyamphetamine (DOM)

25

4-Methylaminorex

25

4-Methyl-N-methylcathinone (mephedrone)

45

4-Methyl-α-ethylaminopentiophenone (4-MEAP)

25

4-Methyl-α-pyrrolidinohexiophenone (MPHP)

25

4-Methyl-α-pyrrolidinopropiophenone (4-MePPP)

25

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol

50

5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog)

40

5F-CUMYL-PINACA

25

5F-EDMB-PINACA

25

5F-MDMB-PICA

25

5F-AB-PINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide

25

5F-CUMYL-P7AICA; (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboximide)

25

5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)

30

5F-AMB (methyl 2-(1-(5-fluoropentyl)-1

H

-indazole-3-carboxamido)-3-methylbutanoate)

30

5F-APINACA; 5F-AKB48 (

N

-(adamantan-1-yl)-1-(5-fluoropentyl)-1

H

-indazole-3-carboxamide)

30

5-Fluoro-PB-22; 5F-PB-22

20

5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1

H-

indol-

3-yl](2,2,3,3-tetramethylcyclopropyl)methanone

25

5-Methoxy-3,4-methylenedioxyamphetamine

25

5-Methoxy-N,N-diisopropyltryptamine

25

5-Methoxy-N,N-dimethyltryptamine

35

AB-CHMINACA

30

AB-FUBINACA

50

AB-PINACA

30

ADB-FUBINACA (

N

-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1

H

-indazole-3-carboxamide)

30

Acetorphine

25

Acetyl Fentanyl

100

Acetyl-

alpha

-methylfentanyl

30

Acetyldihydrocodeine

30

Acetylmethadol

25

Acryl Fentanyl

25

ADB-PINACA (

N

-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1

H

-indazole-3-carboxamide)

50

AH-7921

30

All other tetrahydrocannabinol

1,000

Allylprodine

25

Alphacetylmethadol

25

alpha-

Ethyltryptamine

25

Alphameprodine

25

Alphamethadol

25

Alphaprodine

25

alpha

-Methylfentanyl

30

alpha

-Methylthiofentanyl

30

alpha

-Methyltryptamine (AMT)

25

alpha

-Pyrrolidinobutiophenone (α-PBP)

25

alpha

-Pyrrolidinoheptaphenone (PV8)

25

alpha-

Pyrrolidinohexanophenone (α-PHP)

25

alpha

-Pyrrolidinopentiophenone (α-PVP)

25

Aminorex

25

Anileridine

20

APINCA, AKB48 (

N

-(1-adamantyl)-1-pentyl-1

H

-indazole-3-carboxamide)

25

Benzethidine

25

Benzylmorphine

30

Betacetylmethadol

25

beta

-Hydroxy-3-methylfentanyl

30

beta

-Hydroxyfentanyl

30

beta

-Hydroxythiofentanyl

30

beta

-Methyl fentanyl

30

beta

-Phenyl fentanyl

30

Betameprodine

25

Betamethadol

4

Betaprodine

25

Brorphine

30

Bufotenine

15

Butylone

25

Butyryl fentanyl

30

Cathinone

40

Clonitazene

25

Codeine methylbromide

30

Codeine-N-oxide

192

Cyclopentyl Fentanyl

30

Cyclopropyl Fentanyl

20

Cyprenorphine

25

d-9-THC

384,460

Desomorphine

25

Dextromoramide

25

Diapromide

20

Diethylthiambutene

20

Diethyltryptamine

25

Difenoxin

9,200

Dihydromorphine

753,500

Dimenoxadol

25

Dimepheptanol

25

Dimethylthiambutene

20

Dimethyltryptamine

3,200

Dioxyaphetyl butyrate

25

Dipipanone

25

Drotebanol

25

Ethylmethylthiambutene

25

Etorphine

30

Etoxeridine

25

Fenethylline

30

Fentanyl carbamate

30

Fentanyl related substances

600

FUB-144

25

FUB-AKB48

25

FUB-AMB, MMB-Fubinaca, AMB-Fubinaca

25

Furanyl fentanyl

30

Furethidine

25

gamma

-Hydroxybutyric acid

29,417,000

Heroin

45

Hydromorphinol

40

Hydroxypethidine

25

Ibogaine

30

Isobutyryl Fentanyl

25

JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole)

35

JWH-019 (1-Hexyl-3-(1-naphthoyl)indole)

45

JWH-073 (1-Butyl-3-(1-naphthoyl)indole)

45

JWH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole)

30

JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole)

30

JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole)

35

JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole)

30

JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole)

30

JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole)

30

Ketobemidone

30

Levomoramide

25

Levophenacylmorphan

25

Lysergic acid diethylamide (LSD)

40

MAB-CHMINACA; ADB-CHMINACA (

N

-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1

H

-indazole-3-carboxamide)

30

MDMB-CHMICA; MMB-CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1

H

-indole-3-carboxamido)-3,3-dimethylbutanoate)

30

MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1

H

-indazole-3-carboxamido)-3,3-dimethylbutanoate)

30

MMB-CHMICA-(AMB-CHMICA); Methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate

25

Marihuana

2,000,000

Marihuana extract

500,000

Mecloqualone

30

Mescaline

25

Methaqualone

60

Methcathinone

25

Methiopropamine

30

Methyoxyacetyl fentanyl

30

Methyldesorphine

5

Methyldihydromorphine

25

Morpheridine

25

Morphine methylbromide

5

Morphine methylsulfonate

5

Morphine-N-oxide

150

MT-45

30

Myrophine

25

NM2201; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate

25

N,N

-Dimethylamphetamine

25

Naphyrone

25

N

-Ethyl-1-phenylcyclohexylamine

25

N

-Ethyl-3-piperidyl benzilate

10

N

-Ethylamphetamine

24

N-

Ethylhexedrone

25

N-

Ethylpentylone, ephylone

30

N

-Hydroxy-3,4-methylenedioxyamphetamine

24

N-Methyl-3-Piperidyl Benzilate

30

Nicocodeine

25

Nicomorphine

25

Noracymethadol

25

Norlevorphanol

2,550

Normethadone

25

Normorphine

40

Norpipanone

25

Ocfentanil

25

Ortho-fluorofentanyl, 2-fluorofentanyl

30

ortho

-Fluoroacryl fentanyl

30

ortho

-Fluorobutyryl fentanyl

30

ortho

-Fluoroisobutyryl fentanyl

30

ortho

-Methyl acetylfentanyl

30

ortho

-Methyl methoxyacetyl fentanyl

30

Para-chloroisobutyryl fentanyl

30

Para-fluorofentanyl

25

Para-fluorobutyryl fentanyl

25

para

-Fluoro furanyl fentanyl

30

para

-Methylfentanyl

30

Para-methoxybutyryl fentanyl

30

Parahexyl

5

PB-22; QUPIC

20

Pentedrone

25

Pentylone

25

Phenadoxone

25

Phenampromide

25

Phenomorphan

25

Phenoperidine

25

Phenyl fentanyl

30

Pholcodine

5

Piritramide

25

Proheptazine

25

Properidine

25

Propiram

25

Psilocybin

6,000

Psilocyn

3,500

Racemoramide

25

SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole)

45

SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole)

30

Tetrahydrofuranyl fentanyl

15

Thebacon

25

Thiafentanil

25

Thiofentanyl

25

Thiofuranyl fentanyl

30

THJ-2201 ( [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone)

30

Tilidine

25

Trimeperidine

25

UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone

25

U-47700

30

Valeryl fentanyl

25

Schedule II

1-Phenylcyclohexylamine

15

1-Piperidinocyclohexanecarbonitrile

25

4-Anilino-N-phenethyl-4-piperidine (ANPP)

937,758

Alfentanil

3,260

Alphaprodine

25

Amobarbital

20,100

Bezitramide

25

Carfentanil

20

Cocaine

68,576

Codeine (for conversion)

1,612,500

Codeine (for sale)

27,616,684

D-amphetamine (for sale)

21,200,000

D,l-amphetamine

21,200,000

D-amphetamine (for conversion)

16,068,789

Dextropropoxyphene

35

Dihydrocodeine

156,713

Dihydroetorphine

25

Diphenoxylate (for conversion)

14,100

Diphenoxylate (for sale)

770,800

Ecgonine

68,576

Ethylmorphine

30

Etorphine hydrochloride

32

Fentanyl

731,452

Glutethimide

25

Hydrocodone (for conversion)

1,250

Hydrocodone (for sale)

30,821,224

Hydromorphone

2,743,101

Isomethadone

30

L-amphetamine

30

Levo-alphacetylmethadol (LAAM)

25

Levomethorphan

30

Levorphanol

26,495

Lisdexamfetamine

22,500,000

L-methamphetamine

587,229

Meperidine

856,695

Meperidine Intermediate-A

30

Meperidine Intermediate-B

30

Meperidine Intermediate-C

30

Metazocine

15

Methadone (for sale)

25,619,700

Methadone Intermediate

27,673,600

Methamphetamine

50

D-methamphetamine (for conversion)

485,020

D-methamphetamine (for sale)

40,000

Methylphenidate (for conversion)

15,300,000

Methylphenidate (for sale)

57,438,334

Metopon

25

Moramide-intermediate

25

Morphine (for conversion)

3,376,696

Morphine (for sale)

26,505,995

Nabilone

62,000

Norfentanyl

25

Noroxymorphone (for conversion)

22,044,741

Noroxymorphone (for sale)

376,000

Oliceridine

22,500

Opium (powder)

250,000

Opium (tincture)

530,837

Oripavine

33,010,750

Oxycodone (for conversion)

620,887

Oxycodone (for sale)

57,110,032

Oxymorphone (for conversion)

28,204,371

Oxymorphone (for sale)

563,174

Pentobarbital

30,766,670

Phenazocine

25

Phencyclidine

35

Phenmetrazine

25

Phenylacetone

6,100,000

Piminodine

25

Racemethorphan

5

Racemorphan

5

Remifentanil

3,000

Secobarbital

172,100

Sufentanil

4,000

Tapentadol

13,447,541

Thebaine

57,137,944

List I Chemicals

Ephedrine (for conversion)

100

Ephedrine (for sale)

4,136,000

Phenylpropanolamine (for conversion)

14,878,320

Phenylpropanolamine (for sale)

16,690,000

Pseudoephedrine (for conversion)

1,000

Pseudoephedrine (for sale)

174,246,000

The Administrator further proposes that APQ for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero.

Anne Milgram,

Administrator.

[FR Doc. 2021-24921 Filed 11-10-21; 4:15 pm]

BILLING CODE 4410-09-P